BYSI BeyondSpring Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1677940 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY7,733.3%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA185.0%
ROIC (approx.)—
Asset turnover0.00x
Leverage & solvency
Liabilities / assets23.2%
Debt / equity0.00x
Current ratio0.28x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-0.35x
Accruals ratio250.5%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $0 | $0 |
| R&D expense | $4.39M | $2.64M |
| SG&A expense | $4.56M | $6.11M |
| Operating income | -$8.95M | -$8.75M |
| Pretax income | -$8.62M | -$8.77M |
| Income tax | $90,000 | $96,000 |
| Net income | -$1.01M | -$11.12M |
| EBITDA | -$8.86M | -$8.47M |
| EPS (basic) | -0.02 | -0.28 |
| EPS (diluted) | — | — |
| Balance sheet | ||
| Cash & equivalents | $2.97M | $2.00M |
| Short-term investments | $1.00M | $0 |
| Current assets | $20.88M | $28.58M |
| PP&E, net | $155,000 | $239,000 |
| Total assets | $25.93M | $34.31M |
| Current liabilities | $13.58M | $11.01M |
| Total liabilities | $49.92M | $48.60M |
| Shareholders' equity | -$32.16M | -$32.90M |
| Shares outstanding | 41.12M | 40.32M |
| Cash flow statement | ||
| Operating cash flow | -$19.77M | -$16.44M |
| Capital expenditure | $50,000 | $224,000 |
| Free cash flow | -$19.82M | -$16.67M |
| Investing cash flow | $10.79M | -$12.01M |
| Financing cash flow | $4.97M | $26.79M |
| Depreciation & amortization | $87,000 | $285,000 |
| Stock-based compensation | $722,000 | $2.25M |
Free plan shows the latest 2 periods; Pro shows all 12 🔒
· This company does not report gross profit in XBRL.
· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.